Compare Stocks: BNR, KMDA, PBYI, and PRTA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$14.23 +5.3%	$10.14	$6.79 ▼ $41.72	$142.21M	1.38	50,942 shs	24,500 shs
KMDA Kamada	$8.85 +2.1%	$7.70	$6.50 ▼ $9.35	$498.57M	0.88	151,252 shs	178,119 shs
PBYI Puma Biotechnology	$9.60 +0.8%	$8.77	$4.37 ▼ $9.73	$491.42M	1.24	275,916 shs	327,061 shs
PRTA Prothena	$8.58 +1.4%	$8.91	$7.73 ▼ $11.80	$442.91M	-0.33	325,370 shs	1.83 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+5.25%	+15.88%	+40.97%	+96.28%	+72.07%
KMDA Kamada	+2.08%	+11.74%	+12.17%	+21.07%	+28.26%
PBYI Puma Biotechnology	+0.84%	+5.26%	+1.16%	+26.98%	+121.20%
PRTA Prothena	+1.42%	-3.92%	-7.64%	-3.92%	+6.45%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNR Burning Rock Biotech	$14.23 +5.3%	$10.14	$6.79 ▼ $41.72	$142.21M	1.38	50,942 shs	24,500 shs
KMDA Kamada	$8.85 +2.1%	$7.70	$6.50 ▼ $9.35	$498.57M	0.88	151,252 shs	178,119 shs
PBYI Puma Biotechnology	$9.60 +0.8%	$8.77	$4.37 ▼ $9.73	$491.42M	1.24	275,916 shs	327,061 shs
PRTA Prothena	$8.58 +1.4%	$8.91	$7.73 ▼ $11.80	$442.91M	-0.33	325,370 shs	1.83 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNR Burning Rock Biotech	+5.25%	+15.88%	+40.97%	+96.28%	+72.07%
KMDA Kamada	+2.08%	+11.74%	+12.17%	+21.07%	+28.26%
PBYI Puma Biotechnology	+0.84%	+5.26%	+1.16%	+26.98%	+121.20%
PRTA Prothena	+1.42%	-3.92%	-7.64%	-3.92%	+6.45%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNR Burning Rock Biotech	1.00	Sell	N/A	N/A
KMDA Kamada	3.00	Buy	$13.50	52.54% Upside
PBYI Puma Biotechnology	2.00	Hold	$6.00	-37.50% Downside
PRTA Prothena	2.75	Moderate Buy	$24.57	186.38% Upside

Current Analyst Ratings Breakdown

Latest BNR, KMDA, PBYI, and PRTA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	KMDA Kamada	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$15.00
9/10/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/9/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/21/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C) ➝ Hold (C+)
8/13/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/7/2026	PBYI Puma Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/7/2026	PBYI Puma Biotechnology	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$5.00 ➝ $6.00
7/31/2026	BNR Burning Rock Biotech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	PRTA Prothena	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNR Burning Rock Biotech	$77.16M	1.94	N/A	N/A	$7.28 per share	1.95
KMDA Kamada	$191.85M	2.65	$0.62 per share	14.20	$4.68 per share	1.89
PBYI Puma Biotechnology	$228.40M	2.17	$0.84 per share	11.41	$2.59 per share	3.71
PRTA Prothena	$54.53M	8.24	N/A	N/A	$5.21 per share	1.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNR Burning Rock Biotech	-$7.92M	-$0.87	N/A	N/A	N/A	-13.60%	-12.98%	-8.59%	11/17/2026 (Estimated)
KMDA Kamada	$20.20M	$0.38	23.29	14.75	0.71	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
PBYI Puma Biotechnology	$31.11M	$0.52	18.46	68.57	N/A	11.50%	20.76%	13.22%	11/5/2026 (Estimated)
PRTA Prothena	-$244.09M	-$0.84	N/A	N/A	2.98	-80.68%	-16.45%	-14.51%	11/5/2026 (Estimated)

Latest BNR, KMDA, PBYI, and PRTA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q2 2026	BNR Burning Rock Biotech	-$2.2883	-$0.20	+$2.0883	-$0.25	$19.21 million	$19.84 million
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/6/2026	Q2 2026	PBYI Puma Biotechnology	$0.04	$0.19	+$0.15	$0.16	$53.00 million	$56.50 million
8/6/2026	Q2 2026	PRTA Prothena	-$0.39	-$0.32	+$0.07	-$0.36	$0.42 million	$1.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNR Burning Rock Biotech	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.12	1.36%	N/A	31.58%	N/A
PBYI Puma Biotechnology	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Latest BNR, KMDA, PBYI, and PRTA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNR Burning Rock Biotech	N/A	3.05	2.90
KMDA Kamada	N/A	4.06	2.29
PBYI Puma Biotechnology	N/A	2.91	2.64
PRTA Prothena	N/A	25.05	25.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNR Burning Rock Biotech	30.03%
KMDA Kamada	20.38%
PBYI Puma Biotechnology	61.29%
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
BNR Burning Rock Biotech	30.30%
KMDA Kamada	36.10%
PBYI Puma Biotechnology	22.20%
PRTA Prothena	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNR Burning Rock Biotech	667	10.52 million	7.33 million	Not Optionable
KMDA Kamada	462	57.51 million	36.75 million	Optionable
PBYI Puma Biotechnology	179	51.62 million	40.16 million	Optionable
PRTA Prothena	67	52.35 million	46.91 million	Optionable

BNR, KMDA, PBYI, and PRTA Headlines

Recent News About These Companies

[PRTA] Attention!! Reaching the 'Previous Buy Price' of Big Players Who Sold at the Top! Prothena Dip-Buying Strategy Targeting Chart Pivot Points

September 18 at 11:59 PM | note.comN

Prothena Corporation plc (NASDAQ:PRTA) Receives Average Recommendation of "Moderate Buy" from Analysts

September 18 at 4:28 AM | marketbeat.com

Prothena to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026 | businesswire.com

Prothena (NASDAQ:PRTA) Major Shareholder Purchases 27,000 Shares of Stock

September 4, 2026 | insidertrades.com

Prothena (NASDAQ:PRTA) Major Shareholder Purchases $255,690.00 in Stock

September 3, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Share Price Passes Below Two Hundred Day Moving Average - What's Next?

September 1, 2026 | marketbeat.com

Prothena Corporation plc (NASDAQ:PRTA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 24, 2026 | marketbeat.com

Prothena (NASDAQ:PRTA) Major Shareholder William Scully Purchases 50,000 Shares

August 22, 2026 | insidertrades.com

Prothena (NASDAQ:PRTA) Major Shareholder Buys 50,000 Shares of Stock

August 21, 2026 | marketbeat.com

KMDA or PRTA: Which Is the Better Value Stock Right Now?

August 14, 2026 | zacks.com

RBC Capital Keeps Their Hold Rating on Prothena (PRTA)

August 8, 2026 | theglobeandmail.com

PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

August 7, 2026 | zacks.com

Prothena: Q2 Earnings Snapshot

August 6, 2026 | chron.com

Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Prothena Reports Second Quarter 2026 Financial Results and Business Highlights

August 6, 2026 | businesswire.com

Prothena (NASDAQ:PRTA) Insider Sells $64,897.14 in Stock

July 31, 2026 | insidertrades.com

Prothena to Report Second Quarter 2026 Financial Results on August 6

July 30, 2026 | finance.yahoo.com

PRTA Stock Rises Nearly 11% in Six Months: What's Driving It?

July 9, 2026 | zacks.com

Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases

June 26, 2026 | finance.yahoo.com

SRPT or PRTA: Which Is the Better Value Stock Right Now?

June 24, 2026 | zacks.com

Prothena (NASDAQ:PRTA) Major Shareholder William Scully Buys 20,000 Shares of Stock

June 19, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, KMDA, PBYI, and PRTA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

$14.23 +0.71 (+5.25%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$14.90 +0.67 (+4.74%)

As of 09/18/2026 07:30 PM Eastern

Burning Rock Biotech Limited primarily develops and commercializes cancer therapy selection tests in the People's Republic of China. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoCompass IO, a corresponding test for liquid biopsy samples; OncoScreen IO, a pan-cancer test for tissue samples; and OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC. In addition, the company provides ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal cancers; and brPROPHET, a pre-operative ctDNA detection and post-operative MRD calling for relapsed patients. Further, it has development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; licensing agreement with Oncocyte Corporation to in-license DetermaRx, a risk stratification test for early stage lung cancer patients in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, and IMPACT Therapeutics and Merck KGaA. Additionally, the company offers OncoMaster, an automatic NGS data analysis and report interpretation machine for in-hospital model. Burning Rock Biotech Limited was incorporated in 2014 and is headquartered in Guangzhou, China.

Kamada NASDAQ:KMDA

$8.85 +0.18 (+2.08%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.83 -0.02 (-0.23%)

As of 09/18/2026 07:30 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Puma Biotechnology NASDAQ:PBYI

$9.60 +0.08 (+0.84%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$9.59 -0.01 (-0.16%)

As of 09/18/2026 07:30 PM Eastern

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.

Prothena NASDAQ:PRTA

$8.58 +0.12 (+1.42%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$8.60 +0.03 (+0.29%)

As of 09/18/2026 07:30 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, KMDA, PBYI, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, KMDA, PBYI, and PRTA Earnings

Compare Dividends

Latest BNR, KMDA, PBYI, and PRTA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, KMDA, PBYI, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, KMDA, PBYI, and PRTA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Kamada NASDAQ:KMDA

Puma Biotechnology NASDAQ:PBYI

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BNR, KMDA, PBYI, and PRTA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BNR, KMDA, PBYI, and PRTA Earnings

Compare Dividends

Latest BNR, KMDA, PBYI, and PRTA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BNR, KMDA, PBYI, and PRTA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BNR, KMDA, PBYI, and PRTA Company Descriptions

Burning Rock Biotech NASDAQ:BNR

Kamada NASDAQ:KMDA

Puma Biotechnology NASDAQ:PBYI

Prothena NASDAQ:PRTA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools